Acne Vulgaris Clinical Trial
Official title:
Efficacy and Antimicrobial Activity of Platelet Rich Plasma (PRP) in Acne Vulgaris : A Randomized Controlled Trial
Efficacy and Antimicrobial activity of Platelet Rich Plasma (PRP) in Acne Vulgaris : A randomized controlled trial
Acne vulgaris is one of the most common chronic skin diseases worldwide. The condition
usually starts in adolescence, peaks at the ages of 14 to 19 years and frequently resolves by
mid-twenties.
Acne is characterized by seborrhea, formation of open and closed comedones, erythematous
papules and pustules and in more severe cases present with nodules, deep pustules and pseudo
cysts, in many cases a degree of scarring will ensue.
Its pathophysiology includes hyperseborrhoea, abnormal follicular keratinization and
Propionibacterium acnes proliferation in the pilosebaceous unit.
Acne is a significant clinical problem with sever social, psychological, and emotional
implications. A mainly genetically determined host response pattern combined with bacterial
''triggering'' is generally accepted as being important for the apparently unbalanced
inflammatory activity.
Acne is not an infectious disease, but three major organisms were isolated from the surface
of the skin and the pilosebaceous duct of patients with acne including Propionibacterium
acne, Staphylococcus epidermidis and Malassezia furfur.
Platelet rich plasma is a good choice for the treatment of acne and atrophic scars
reminiscent of the course of the disease. In addition, for being autologous, it reduces the
possibility of side effects, such as skin dryness and rejection.
It was demonstrated that PRP accelerates the healing process, regulates inflammation and
promotes healing by inhibiting the P. acnes bacteria, additionally restoring collagen). The
PRP's mechanism of action also involves the release of powerful antimicrobial peptides from
the platelets' alpha granules.
Although there are few studies on the PRP's effectiveness in acne, it emerges as a potential
therapeutic option in Dermatology and Aesthetic Medicine.
Due to development of resistance in microorganisms causing acne to common antibiotics and
differences in species and strains of the microorganisms in different regions, this study
will be undertaken to determine bacteria involve in acne vulgaris and the effect of PRP on
it.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04321070 -
Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris
|
Phase 1 | |
| Recruiting |
NCT05755256 -
The Impact of Probiotics on Skin Hydration in Youth With Mild Acne
|
Phase 2 | |
| Completed |
NCT05131373 -
Safety, Tolerability, and Immunogenicity of ORI-A-ce001 for the Treatment of Acne Vulgaris
|
Phase 1 | |
| Completed |
NCT01445301 -
Study STF115287, a Clinical Confirmation Study of GSK2585823 in the Treatment of Acne Vulgaris in Japanese Subjects
|
Phase 3 | |
| Completed |
NCT03303170 -
Non-Significant Risk Study of Sebacia Microparticles in the Treatment of Facial Acne Vulgaris
|
N/A | |
| Completed |
NCT04698239 -
Clinical Evaluation of the Safety and Benefits of the Milesman 445 nm Blue Laser on Inflammatory Acne Lesions.
|
N/A | |
| Completed |
NCT02886715 -
A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris
|
Phase 3 | |
| Terminated |
NCT02924428 -
Venus Versa Diamondpolar Applicator Treatment Followed by AC Dual Applicator Treatment for Facial Acne Vulgaris
|
N/A | |
| Completed |
NCT02709902 -
Study Comparing Adapalene/BP Gel to EPIDUO® FORTE and Both to a Placebo Control in Treatment of Acne Vulgaris
|
Phase 1 | |
| Not yet recruiting |
NCT02491060 -
A Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris
|
Phase 3 | |
| Not yet recruiting |
NCT02535871 -
A Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris
|
Phase 3 | |
| Not yet recruiting |
NCT02525822 -
Study to Compare the Safety and Efficacy of IDP-123 Lotion to Tazorac Cream in the Treatment of Acne Vulgaris
|
Phase 2 | |
| Completed |
NCT02250430 -
A Phase 1 Study Assessing Local Cutaneous Effects of SB204
|
Phase 1 | |
| Completed |
NCT02913001 -
The Effect of a Low Glycemic Load Diet on Hormonal Markers Associated With Acne
|
N/A | |
| Completed |
NCT01694810 -
Cutaneous Tolerability and Safety of NVN1000 Topical Gel in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT01769664 -
A Study Comparing Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel to Duac® Topical Gel in the Treatment of Acne Vulgaris
|
Phase 1 | |
| Completed |
NCT01727440 -
Identifying the Genetic Predictors of Severe Acne Vulgaris and the Outcome of Oral Isotretinoin Treatment
|
N/A | |
| Completed |
NCT01194375 -
A Dose-Ranging Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris
|
Phase 2 | |
| Completed |
NCT01706250 -
U0289-401: Eight Week, Split-face, Study to Determine and Compare the Efficacy and Tolerability of MAXCLARITY™ II to PROACTIV™
|
Phase 4 | |
| Completed |
NCT02524665 -
8 Week Study to Evaluate and Compare the Efficacy and Tolerability of MAXCLARITY II and MURAD To Treat Acne
|
Phase 4 |